August 14, 2009 (FinancialWire) (Investrend Broadcast Syndicate) — Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) (current market cap: US$26.7 mil.) will webcast their Second Quarter 2009 Financial Results today, August 14, at 8:00 a.m. EDT. The webcast is being carried by VCall, and is directly accessible via the VCall website (http://infoescrow.net/f/?u=http://www.investorcalendar.com/IC/ClientPage.asp?ID=148641).

According to Skystar Bio-Pharmaceutical, “Skystar Bio-Pharmaceutical Co. is a high-tech bio-pharmaceutical enterprise, engaged in research, development, and production of bio-pharmaceutical products. The Company’s principal products are comprised of veterinary drugs, fodder additive, microorganism preparation products; and it has a veterinary bio-pharmaceutical research and development center located in Xi’an, China.”

Conference calls are often impacted by market trends, geopolitical conditions, news coming from conferences and economic releases. FinancialWire(tm) provides complete, daily conference call schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “Daily FirstAlert(tm)” (http://www.financialwire.net/news-alerts/), as well as free annual reports on those and thousands of other companies via the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php).  Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.